Obesity Clinical Trial
Official title:
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
Verified date | July 2022 |
Source | Temple University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Objective: To show that a 1-2 day reduction of caloric intake can reduce the insulin resistance produced by several days of overnutrition. Approach: Healthy volunteers will be admitted to the Clinical Research Center and undergo a baseline euglycemic-hyperinsulinemic clamp study to assess their insulin resistance. Subjects will then start on an overnutrition program for 4 days consisting of 3 meals and 3 snacks containing ~6,000 Kcal/24hours. A second clamp study will be performed on day 5 to demonstrate the overnutrition induced increase in insulin resistance. Starting on day 5 the subject's caloric intake will be reduced to ~1,000 Kcal for 2 days (day 5 and 6). After that on the morning of day 7, a third hyperinsulinemic-euglycemic clamp will be performed to determine whether the reduced caloric intake did reduce insulin resistance and the volunteer will be discharged from the Clinical Research Center.
Status | Active, not recruiting |
Enrollment | 1 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: Healthy non-obese men and women - Exclusion Criteria: Subjects with diabetes or a history of obesity surgery or with more than modest health problems - |
Country | Name | City | State |
---|---|---|---|
United States | Temple University Hospital | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Temple University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in insulin resistance | Insulin resistance will be determined by measuring changes in insulin-stimulated total body glucose uptake during euglycemic hyperinsulinemic clamping | baseline, day 4 and day 7 | |
Primary | Changes in oxidative stress | 24 hour urine collections analyzed for isoprostane content | baseline, day1, day 2, day 3, day 4, day 5, day 6, day 7 | |
Primary | Changes in energy expenditure | Changes in energy expenditure will be assessed with a metabolic cart (indirect calorimetry) | baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7 | |
Primary | Changes in weight | Subjects will be weighed daily | baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7 | |
Primary | Changes in body composition | Body composition will be determined by bioelectric impedance analysis | baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7 | |
Secondary | Changes in blood glucose levels | Daily blood samples will be analyzed to determine glucose levels of glucose. | baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7 | |
Secondary | Changes in blood levels of insulin | Daily blood samples will be analyzed to determine insulin levels | Baseline, day1 day2, day 3, day 4, day 5, day 6, day 7 | |
Secondary | Changes in blood levels of free fatty acids | Daily blood samples will be analyzed to determine free fatty acid levels | Baseline, day1 , day 2, day 3, day 4, day 5, day 6, day 7 | |
Secondary | Changes in blood ketone levels | Daily blood samples will be analyzed to determine ketone levels | baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7 | |
Secondary | Changes in glucagon levels | Daily blood samples will be analyzed to determine glucagon levels | baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |